Search Results - kotohiko+kimura

3 Results

Sort By:

C11620: Novel Treatment for Heart Attack

Novelty: The outlined invention features the novel therapeutic implications of a drug in preventing cardiac cell loss that occurs in myocardium infraction.Value Proposition: The technology describes the application of a drug to treat a major public health problem for which there is no current medical treatment option. The main features of the invention...

Published: 3/13/2025 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cardiovascular Diseases, Disease Indication, Myocardial Infarction, Myocardial Infarction (MI), Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular > Myocardial Infarction, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities

Rapid Induction of Human Cancer Cell Death by Synergistic Treatment of Tetra-O-Methyl Nordihydroguaiaretic Acid (M4N, Terameprocol) with 7-Hydroxystaurosporine (UCN-01)

Value Proposition: Tetra-O-methyl nordihydroguaiaretic acid (M4N, EM1421, Terameprocol), a novel transcription inhibitor, is an effective anticancer agent with excellent safety profile (Smolewski, P. Idrugs 11, 204-214, 2008). In the current study, we report an enhancement of anticancer activities of M4N in combination with 7-hydroxystaurosporine (UCN-01),...

Published: 3/13/2025 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

Rapid Induction of Cancer Cell Death by Synergistic Treatment of Tetra-O-methyl Nordihydroguaiaretic Acid (M4N) with either Rottlerin or Ly294002

Technical Details: M4N is an anti-cancer drug candidate, which is currently under the first phase of clinical trials. Although M4N can reduce tumor cell growth; it fails to induce quick tumor cell death. JHU scientists showed that the combination treatment of M4N with either two specific kinase inhibitors overcomes this problem. In vivo study demonstrated...

Published: 3/13/2025 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Targeted Therapy, Combination, Disease Indication, Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type